1,922 results on '"Roobol, Monique J."'
Search Results
102. Prostate Carcinoma Grade and Length But Not Cribriform Architecture at Positive Surgical Margins Are Predictive for Biochemical Recurrence After Radical Prostatectomy
- Author
-
Hollemans, Eva, Verhoef, Esther I., Bangma, Chris H., Rietbergen, John, Helleman, Jozien, Roobol, Monique J., and van Leenders, Geert J.L.H.
- Published
- 2020
- Full Text
- View/download PDF
103. How to follow the new EU Council recommendation and improve prostate cancer early detection: the Prostaforum 2022 declaration
- Author
-
Májek, Ondřej, Babjuk, Marek, Roobol, Monique J., Bratt, Ola, Van Poppel, Hendrik, Zachoval, Roman, Ferda, Jiří, Koudelková, Marcela, Ngo, Ondřej, Gregor, Jakub, Collen, Sarah, Hejduk, Karel, Dušek, Ladislav, Válek, Vlastimil, and Urology
- Subjects
SDG 3 - Good Health and Well-being - Abstract
An updated Council of the EU recommendation on cancer screening was adopted in December 2022 during the Czech EU presidency. The recommendation included prostate cancer as a suitable target disease for organised screening, and invited countries to proceed with piloting and further research. To support further discussions and actions to promote early detection of prostate cancer, an international conference in November 2022 (Prostaforum 2022) resulted in a joint declaration. Here we describe the EU policy background, summarise the preparation of the declaration and the key underlying evidence and expert recommendations, and report the text of the declaration. The declaration summarises the striking inequalities in prostate cancer burden in Europe and calls on all stakeholders to consider and support concrete steps for advancement of organised early detection of prostate cancer. Our aim is to request endorsement of the text and potential initiation of practical actions by all stakeholders to support the aims of the declaration. Patient summary: Prostate cancer is among the most frequent cancers and is one of the most common causes of cancer death among men. The European Union has recommended new pilot programmes for prostate cancer screening. The Prostaforum 2022 declaration invites all stakeholders to support this new recommendation with specific steps.
- Published
- 2023
104. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci
- Author
-
Schumacher, Fredrick R., Al Olama, Ali Amin, Berndt, Sonja I., Benlloch, Sara, Ahmed, Mahbubl, Saunders, Edward J., Dadaev, Tokhir, Leongamornlert, Daniel, Anokian, Ezequiel, Cieza-Borrella, Clara, Goh, Chee, Brook, Mark N., Sheng, Xin, Fachal, Laura, Dennis, Joe, Tyrer, Jonathan, Muir, Kenneth, Lophatananon, Artitaya, Stevens, Victoria L., Gapstur, Susan M., Carter, Brian D., Tangen, Catherine M., Goodman, Phyllis J., Thompson, Jr, Ian M., Batra, Jyotsna, Chambers, Suzanne, Moya, Leire, Clements, Judith, Horvath, Lisa, Tilley, Wayne, Risbridger, Gail P., Gronberg, Henrik, Aly, Markus, Nordström, Tobias, Pharoah, Paul, Pashayan, Nora, Schleutker, Johanna, Tammela, Teuvo L. J., Sipeky, Csilla, Auvinen, Anssi, Albanes, Demetrius, Weinstein, Stephanie, Wolk, Alicja, Håkansson, Niclas, West, Catharine M. L., Dunning, Alison M., Burnet, Neil, Mucci, Lorelei A., Giovannucci, Edward, Andriole, Gerald L., Cussenot, Olivier, Cancel-Tassin, Géraldine, Koutros, Stella, Beane Freeman, Laura E., Sorensen, Karina Dalsgaard, Orntoft, Torben Falck, Borre, Michael, Maehle, Lovise, Grindedal, Eli Marie, Neal, David E., Donovan, Jenny L., Hamdy, Freddie C., Martin, Richard M., Travis, Ruth C., Key, Tim J., Hamilton, Robert J., Fleshner, Neil E., Finelli, Antonio, Ingles, Sue Ann, Stern, Mariana C., Rosenstein, Barry S., Kerns, Sarah L., Ostrer, Harry, Lu, Yong-Jie, Zhang, Hong-Wei, Feng, Ninghan, Mao, Xueying, Guo, Xin, Wang, Guomin, Sun, Zan, Giles, Graham G., Southey, Melissa C., MacInnis, Robert J., FitzGerald, Liesel M., Kibel, Adam S., Drake, Bettina F., Vega, Ana, Gómez-Caamaño, Antonio, Szulkin, Robert, Eklund, Martin, Kogevinas, Manolis, Llorca, Javier, Castaño-Vinyals, Gemma, Penney, Kathryn L., Stampfer, Meir, Park, Jong Y., Sellers, Thomas A., Lin, Hui-Yi, Stanford, Janet L., Cybulski, Cezary, Wokolorczyk, Dominika, Lubinski, Jan, Ostrander, Elaine A., Geybels, Milan S., Nordestgaard, Børge G., Nielsen, Sune F., Weischer, Maren, Bisbjerg, Rasmus, Røder, Martin Andreas, Iversen, Peter, Brenner, Hermann, Cuk, Katarina, Holleczek, Bernd, Maier, Christiane, Luedeke, Manuel, Schnoeller, Thomas, Kim, Jeri, Logothetis, Christopher J., John, Esther M., Teixeira, Manuel R., Paulo, Paula, Cardoso, Marta, Neuhausen, Susan L., Steele, Linda, Ding, Yuan Chun, De Ruyck, Kim, De Meerleer, Gert, Ost, Piet, Razack, Azad, Lim, Jasmine, Teo, Soo-Hwang, Lin, Daniel W., Newcomb, Lisa F., Lessel, Davor, Gamulin, Marija, Kulis, Tomislav, Kaneva, Radka, Usmani, Nawaid, Singhal, Sandeep, Slavov, Chavdar, Mitev, Vanio, Parliament, Matthew, Claessens, Frank, Joniau, Steven, Van den Broeck, Thomas, Larkin, Samantha, Townsend, Paul A., Aukim-Hastie, Claire, Gago-Dominguez, Manuela, Castelao, Jose Esteban, Martinez, Maria Elena, Roobol, Monique J., Jenster, Guido, van Schaik, Ron H. N., Menegaux, Florence, Truong, Thérèse, Koudou, Yves Akoli, Xu, Jianfeng, Khaw, Kay-Tee, Cannon-Albright, Lisa, Pandha, Hardev, Michael, Agnieszka, Thibodeau, Stephen N., McDonnell, Shannon K., Schaid, Daniel J., Lindstrom, Sara, Turman, Constance, Ma, Jing, Hunter, David J., Riboli, Elio, Siddiq, Afshan, Canzian, Federico, Kolonel, Laurence N., Le Marchand, Loic, Hoover, Robert N., Machiela, Mitchell J., Cui, Zuxi, Kraft, Peter, Amos, Christopher I., Conti, David V., Easton, Douglas F., Wiklund, Fredrik, Chanock, Stephen J., Henderson, Brian E., Kote-Jarai, Zsofia, Haiman, Christopher A., Eeles, Rosalind A., The Profile Study, Australian Prostate Cancer BioResource (APCB), The IMPACT Study, Canary PASS Investigators, Breast and Prostate Cancer Cohort Consortium (BPC3), The PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, Cancer of the Prostate in Sweden (CAPS), Prostate Cancer Genome-wide Association Study of Uncommon Susceptibility Loci (PEGASUS), and The Genetic Associations and Mechanisms in Oncology (GAME-ON)/Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE) Consortium
- Published
- 2018
- Full Text
- View/download PDF
105. A literature review to understand health literacy in men with prostate cancer on active surveillance
- Author
-
Beyer, Katharina, primary, Remmers, Sebastiaan, additional, Hemelrijck, Mieke Van, additional, Roobol, Monique J., additional, and Venderbos, Lionne D. F., additional
- Published
- 2023
- Full Text
- View/download PDF
106. Mapping European Association of Urology Guideline Practice Across Europe: An Audit of Androgen Deprivation Therapy Use Before Prostate Cancer Surgery in 6598 Cases in 187 Hospitals Across 31 European Countries
- Author
-
MacLennan, Steven, primary, Azevedo, Nuno, additional, Duncan, Eilidh, additional, Dunsmore, Jennifer, additional, Fullwood, Louise, additional, Lumen, Nicolaas, additional, Plass, Karin, additional, Ribal, Maria J., additional, Roobol, Monique J., additional, Nieboer, Daan, additional, Schouten, Natasha, additional, Skolarus, Ted A., additional, Smith, Emma Jane, additional, N'Dow, James, additional, Mottet, Nicolas, additional, Briganti, Alberto, additional, Heidegger, Isabel, additional, Resch, Johannes Mischinger Irene, additional, Turba, Simon, additional, Zeder, Robin, additional, Lodeta, Braninimir, additional, Van Praet, Charles, additional, Ghysel, Christophe, additional, Arentsen, Harm C., additional, Beysens, Matthias, additional, Vinckier, Marie-Hélène, additional, Mottrie, Alexandre, additional, de Groote, Ruben, additional, Timev, Aleksandar Ivanov, additional, Georgiev, Marincho Ivanov, additional, Yanev, Krassimir Prodanov, additional, Mladenov, Boris, additional, Ivanov, Atanas Slavchev, additional, Antonov, Petar, additional, Valkanov, Stanislav, additional, Tomašković, Igor, additional, Kulis, Tomislav, additional, Bokarica, Pero, additional, Pavlović, Oliver, additional, Krajina, Vinko, additional, Situm, Marijan, additional, Boban, Toni, additional, Soric, Tomislav, additional, Vidic, Ivan, additional, Benko, Goran, additional, Peršec, Zoran, additional, Sović, Tomislav, additional, Zachoval, Roman, additional, Stejskal, Jiri, additional, Capoun, Otakar, additional, Pitra, Tomáš, additional, Gojdič, Marek, additional, Babjuk, Marek, additional, Novák, Vojtěch, additional, Grepl, Michal, additional, Broul, Marek, additional, Novák, Jan, additional, Lund, Lars, additional, Nordström Joensen, Ulla, additional, Borre, Michael, additional, Veskimäe, Priit, additional, Baum, Peep, additional, Tamm, Toomas, additional, Okas, Rauno, additional, Jämsä, Pyry, additional, Lahdensuo, Kanerva, additional, Siltari, Sirkku, additional, Seikkula, Heikki, additional, Palmberg, Christian, additional, Isotalo, Taina, additional, Fiard, Gaelle, additional, Verrier, Cecile, additional, Wiedemann, Laura, additional, Lecornet, Emilie, additional, Leon, Priscilla, additional, Millet, Clementine, additional, Ponzio, Charles, additional, Ploussard, Guillaume, additional, Xylinas, Evanguelos, additional, Ingels, Alexandre, additional, Bigot, Pierre, additional, Le Corre, Vincent, additional, Audenet, François, additional, Berg, Sebastian, additional, Palisaar, Rein-Jueri, additional, Heidenreich, Axel, additional, Seelemeyer, Felix, additional, Krege, Susanne, additional, Leyh-Bannurah, Sami-Ramzi, additional, Witt, Jörn H., additional, Abdirahman, Ayanle, additional, Truß, Michael C., additional, Kranz, Jennifer, additional, Andreas, Karagiannis, additional, Vassileios, Tzortzis, additional, Andreas, Andreou, additional, Paparidis, Spyridon, additional, Davis, Nikolaos Ferakis Niall F., additional, Keane, Kevin G., additional, Fuentes, Adrian, additional, Scuderi, Simone, additional, Barletta, Francesco, additional, Manfredi, Matteo, additional, Porpiglia, Francesco, additional, Cerruto, Maria Angela, additional, Antonelli, Alessandro, additional, Esperto, Francesco, additional, Rossanese, Marta, additional, Veneziano, Domenico, additional, Castelli, Tommaso, additional, La Rocca, Roberto, additional, Scarcia, Marcello, additional, Mantica, Guglielmo, additional, Rebuffo, Silvia, additional, Pomara, Giorgio, additional, Pavan, Nicola, additional, Silvestri, Tommaso, additional, Reale, Giulio Francesco, additional, Polara, Andrea, additional, Falagario, Ugo Giovanni, additional, Carrieri, Giuseppe, additional, Ferrari, Giovanni, additional, Brausi, Maurizio, additional, Orecchia, Luca, additional, Annino, Filippo, additional, Kazlauskas, Gražvydas, additional, Stavridis, Sotir, additional, Radovic, Nenad, additional, Vukovic, Marko, additional, van der Slot, Margaretha Adriana, additional, Bruins, Harman Maxim, additional, van Oort, Inge, additional, Witjes, Fred, additional, van der Poel, Henk, additional, Beisland, Christian, additional, Lilleåsenm, Gunder, additional, Müller, Stig, additional, Haug, Erik S., additional, Dimmen, Magne, additional, Czech, Anna K., additional, Nyk, Lukasz, additional, Jaskulski, Jaroslaw, additional, Ratajczyk, Krzysztof, additional, Braga, Isaac, additional, Pereira, João, additional, Lúcio, Rui, additional, Pina, João, additional, da Silva, Edgar Miguel Calvo Loureiro Tavares, additional, Furriel, Frederico, additional, Mota, Paulo, additional, Rodrigues, Miguel, additional, Radavoi, George Daniel, additional, Crisan, Nicolae, additional, Andras, Iulia, additional, Robert, Stoica, additional, Bratu, Ovidiu, additional, Surcel, Cristian, additional, Kotov, Sergei, additional, Malkhasyan, Vigen, additional, Petrov, Sergei, additional, Reva, Sergei, additional, Bumbasirevic, Uros, additional, Kováčik, Viktor, additional, Perečinský, Ivan, additional, Rybár, Ľuboš, additional, Šulgan, Ján, additional, Briš, Lukáš, additional, Jursová, Katarína, additional, Chovan, Miroslav, additional, Kička, Tomáš, additional, Taskovska, Milena, additional, Kovačič, Rok, additional, Miklavžina, Andraž, additional, Alvarez-Maestro, Mario, additional, De Castro, Javier Mayor, additional, Aragón-Chamizo, Juan, additional, Sutil, Raquel Sopeña, additional, Perrello, Carmen Garau, additional, Vilaseca, Antoni, additional, Perez, Jorge Huguet, additional, Ovide, Julia Aumatell, additional, Planas, Jacques, additional, Borque-Fernando, Angel, additional, Sánchez-Izquierdo, Elena, additional, Jimenez, Jose Luis Marenco, additional, Lendínez-Cano, Guillermo, additional, Puche-Sanz, Ignacio, additional, Garcia-Baquero, Rodrigo, additional, Esteban, Mario Domínguez, additional, Pérez-Fentes, Daniel, additional, Serván, Patricia Parra, additional, Koskela, Lotta Renström, additional, Stranne, Johan, additional, Scholtz, Bianca, additional, Torbrand, Christian, additional, Wagenius, Magnus, additional, Ugge, Henrik, additional, Örtegren, Joakim, additional, Langenauer, Janine, additional, Zumstein, Valentin, additional, Schmid, Hans Peter, additional, Rieken, Malte, additional, Saba, Karim, additional, Strebel, Raeto T., additional, Mortezavi, Ashkan, additional, Rentsch, Cyrill, additional, Roth, Beat, additional, Eberli, Daniel, additional, Pascal, Oechslin, additional, Auer, Rebecca, additional, John, Hubert, additional, Thalmann, George N., additional, Baltacı, Sümer, additional, Mungan, Aydın, additional, Sözen, Sinan, additional, Cetin, Serhat, additional, Aslan, Guven, additional, Türkeri, Levent, additional, İzol, Volkan, additional, Demirdağ, Çetin, additional, Ozden, Sami Berk, additional, Toktaş, Gökhan, additional, Sarikaya, Şaban, additional, Tinay, İlker, additional, Müezzinoğlu, Talha, additional, Erbatu, Oguzcan, additional, Sagnak, Levent, additional, Akdoğan, Bülent, additional, Can, Cavit, additional, Şahin, Hayrettin, additional, Yazıcı, Cenk Murat, additional, Volkov, Serhii, additional, Shulyak, Olexandr, additional, Douglas, David, additional, Hemmant, Joshua, additional, El-Taji, Omar, additional, Ahmad, Imran, additional, Nalagatla, Sarika, additional, Janebdar, Husay, additional, Veeratterapillay, Rajan, additional, Rai, Bhavan, additional, Conroy, Samantha, additional, Cumberbatch, Marcus, additional, and Malde, Sachin, additional
- Published
- 2023
- Full Text
- View/download PDF
107. External validation of the Rotterdam Prostate Cancer Risk Calculator within a Dutch high-risk clinical cohort
- Author
-
Hagens, Marinus J., primary, Stelwagen, Piter J., additional, Veerman, Hans, additional, Rynja, Sybren P., additional, Smeenge, Martijn, additional, van der Noort, Vincent, additional, Roeleveld, Ton A., additional, van Kesteren, Jolien, additional, Remmers, Sebastiaan, additional, Roobol, Monique J., additional, van Leeuwen, Pim J., additional, and van der Poel, Henk G., additional
- Published
- 2023
- Full Text
- View/download PDF
108. Active Surveillance for Prostate Cancer: Past, Current, and Future Trends
- Author
-
de Vos, Ivo I., primary, Luiting, Henk B., additional, and Roobol, Monique J., additional
- Published
- 2023
- Full Text
- View/download PDF
109. Screening for prostate cancer: evidence, ongoing trials, policies and knowledge gaps
- Author
-
Bratt, Ola, primary, Auvinen, Anssi, additional, Arnsrud Godtman, Rebecka, additional, Hellström, Mikael, additional, Hugosson, Jonas, additional, Lilja, Hans, additional, Wallström, Jonas, additional, and Roobol, Monique J, additional
- Published
- 2023
- Full Text
- View/download PDF
110. Supplementary Materials and Methods from A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk
- Author
-
Travis, Ruth C., primary, Appleby, Paul N., primary, Martin, Richard M., primary, Holly, Jeff M.P., primary, Albanes, Demetrius, primary, Black, Amanda, primary, Bueno-de-Mesquita, H. Bas, primary, Chan, June M., primary, Chen, Chu, primary, Chirlaque, Maria-Dolores, primary, Cook, Michael B., primary, Deschasaux, Mélanie, primary, Donovan, Jenny L., primary, Ferrucci, Luigi, primary, Galan, Pilar, primary, Giles, Graham G., primary, Giovannucci, Edward L., primary, Gunter, Marc J., primary, Habel, Laurel A., primary, Hamdy, Freddie C., primary, Helzlsouer, Kathy J., primary, Hercberg, Serge, primary, Hoover, Robert N., primary, Janssen, Joseph A.M.J.L., primary, Kaaks, Rudolf, primary, Kubo, Tatsuhiko, primary, Le Marchand, Loic, primary, Metter, E. Jeffrey, primary, Mikami, Kazuya, primary, Morris, Joan K., primary, Neal, David E., primary, Neuhouser, Marian L., primary, Ozasa, Kotaro, primary, Palli, Domenico, primary, Platz, Elizabeth A., primary, Pollak, Michael N., primary, Price, Alison J., primary, Roobol, Monique J., primary, Schaefer, Catherine, primary, Schenk, Jeannette M., primary, Severi, Gianluca, primary, Stampfer, Meir J., primary, Stattin, Pär, primary, Tamakoshi, Akiko, primary, Tangen, Catherine M., primary, Touvier, Mathilde, primary, Wald, Nicholas J., primary, Weiss, Noel S., primary, Ziegler, Regina G., primary, Key, Timothy J., primary, and Allen, Naomi E., primary
- Published
- 2023
- Full Text
- View/download PDF
111. Supplementary Figure Legends from A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk
- Author
-
Travis, Ruth C., primary, Appleby, Paul N., primary, Martin, Richard M., primary, Holly, Jeff M.P., primary, Albanes, Demetrius, primary, Black, Amanda, primary, Bueno-de-Mesquita, H. Bas, primary, Chan, June M., primary, Chen, Chu, primary, Chirlaque, Maria-Dolores, primary, Cook, Michael B., primary, Deschasaux, Mélanie, primary, Donovan, Jenny L., primary, Ferrucci, Luigi, primary, Galan, Pilar, primary, Giles, Graham G., primary, Giovannucci, Edward L., primary, Gunter, Marc J., primary, Habel, Laurel A., primary, Hamdy, Freddie C., primary, Helzlsouer, Kathy J., primary, Hercberg, Serge, primary, Hoover, Robert N., primary, Janssen, Joseph A.M.J.L., primary, Kaaks, Rudolf, primary, Kubo, Tatsuhiko, primary, Le Marchand, Loic, primary, Metter, E. Jeffrey, primary, Mikami, Kazuya, primary, Morris, Joan K., primary, Neal, David E., primary, Neuhouser, Marian L., primary, Ozasa, Kotaro, primary, Palli, Domenico, primary, Platz, Elizabeth A., primary, Pollak, Michael N., primary, Price, Alison J., primary, Roobol, Monique J., primary, Schaefer, Catherine, primary, Schenk, Jeannette M., primary, Severi, Gianluca, primary, Stampfer, Meir J., primary, Stattin, Pär, primary, Tamakoshi, Akiko, primary, Tangen, Catherine M., primary, Touvier, Mathilde, primary, Wald, Nicholas J., primary, Weiss, Noel S., primary, Ziegler, Regina G., primary, Key, Timothy J., primary, and Allen, Naomi E., primary
- Published
- 2023
- Full Text
- View/download PDF
112. Supplementary Tables 1 through 8 and Supplementary Figures 1 through 15 from A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk
- Author
-
Travis, Ruth C., primary, Appleby, Paul N., primary, Martin, Richard M., primary, Holly, Jeff M.P., primary, Albanes, Demetrius, primary, Black, Amanda, primary, Bueno-de-Mesquita, H. Bas, primary, Chan, June M., primary, Chen, Chu, primary, Chirlaque, Maria-Dolores, primary, Cook, Michael B., primary, Deschasaux, Mélanie, primary, Donovan, Jenny L., primary, Ferrucci, Luigi, primary, Galan, Pilar, primary, Giles, Graham G., primary, Giovannucci, Edward L., primary, Gunter, Marc J., primary, Habel, Laurel A., primary, Hamdy, Freddie C., primary, Helzlsouer, Kathy J., primary, Hercberg, Serge, primary, Hoover, Robert N., primary, Janssen, Joseph A.M.J.L., primary, Kaaks, Rudolf, primary, Kubo, Tatsuhiko, primary, Le Marchand, Loic, primary, Metter, E. Jeffrey, primary, Mikami, Kazuya, primary, Morris, Joan K., primary, Neal, David E., primary, Neuhouser, Marian L., primary, Ozasa, Kotaro, primary, Palli, Domenico, primary, Platz, Elizabeth A., primary, Pollak, Michael N., primary, Price, Alison J., primary, Roobol, Monique J., primary, Schaefer, Catherine, primary, Schenk, Jeannette M., primary, Severi, Gianluca, primary, Stampfer, Meir J., primary, Stattin, Pär, primary, Tamakoshi, Akiko, primary, Tangen, Catherine M., primary, Touvier, Mathilde, primary, Wald, Nicholas J., primary, Weiss, Noel S., primary, Ziegler, Regina G., primary, Key, Timothy J., primary, and Allen, Naomi E., primary
- Published
- 2023
- Full Text
- View/download PDF
113. Data from A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk
- Author
-
Travis, Ruth C., primary, Appleby, Paul N., primary, Martin, Richard M., primary, Holly, Jeff M.P., primary, Albanes, Demetrius, primary, Black, Amanda, primary, Bueno-de-Mesquita, H. Bas, primary, Chan, June M., primary, Chen, Chu, primary, Chirlaque, Maria-Dolores, primary, Cook, Michael B., primary, Deschasaux, Mélanie, primary, Donovan, Jenny L., primary, Ferrucci, Luigi, primary, Galan, Pilar, primary, Giles, Graham G., primary, Giovannucci, Edward L., primary, Gunter, Marc J., primary, Habel, Laurel A., primary, Hamdy, Freddie C., primary, Helzlsouer, Kathy J., primary, Hercberg, Serge, primary, Hoover, Robert N., primary, Janssen, Joseph A.M.J.L., primary, Kaaks, Rudolf, primary, Kubo, Tatsuhiko, primary, Le Marchand, Loic, primary, Metter, E. Jeffrey, primary, Mikami, Kazuya, primary, Morris, Joan K., primary, Neal, David E., primary, Neuhouser, Marian L., primary, Ozasa, Kotaro, primary, Palli, Domenico, primary, Platz, Elizabeth A., primary, Pollak, Michael N., primary, Price, Alison J., primary, Roobol, Monique J., primary, Schaefer, Catherine, primary, Schenk, Jeannette M., primary, Severi, Gianluca, primary, Stampfer, Meir J., primary, Stattin, Pär, primary, Tamakoshi, Akiko, primary, Tangen, Catherine M., primary, Touvier, Mathilde, primary, Wald, Nicholas J., primary, Weiss, Noel S., primary, Ziegler, Regina G., primary, Key, Timothy J., primary, and Allen, Naomi E., primary
- Published
- 2023
- Full Text
- View/download PDF
114. Circulating insulin-like growth factors and risks of overall, aggressive and early-onset prostate cancer : a collaborative analysis of 20 prospective studies and Mendelian randomization analysis
- Author
-
Watts, Eleanor L., Perez-Cornago, Aurora, Fensom, Georgina K., Smith-Byrne, Karl, Noor, Urwah, Andrews, Colm D., Gunter, Marc J., Holmes, Michael V., Martin, Richard M., Tsilidis, Konstantinos K., Albanes, Demetrius, Barricarte, Aurelio, Bueno-De-Mesquita, H. Bas, Cohn, Barbara A., Deschasaux-Tanguy, Melanie, Dimou, Niki L., Ferrucci, Luigi, Flicker, Leon, Freedman, Neal D., Giles, Graham G., Giovannucci, Edward L., Haiman, Christopher A., Hankey, Graham J., Holly, Jeffrey M. P., Huang, Jiaqi, Huang, Wen-Yi, Hurwitz, Lauren M., Kaaks, Rudolf, Kubo, Tatsuhiko, Le Marchand, Loic, Macinnis, Robert J., Männistö, Satu, Metter, E. Jeffrey, Mikami, Kazuya, Mucci, Lorelei A., Olsen, Anja W., Ozasa, Kotaro, Palli, Domenico, Penney, Kathryn L., Platz, Elizabeth A., Pollak, Michael N., Roobol, Monique J., Schaefer, Catherine A., Schenk, Jeannette M., Stattin, Pär, Tamakoshi, Akiko, Thysell, Elin, Tsai, Chiaojung Jillian, Touvier, Mathilde, Van Den Eeden, Stephen K., Weiderpass, Elisabete, Weinstein, Stephanie J., Wilkens, Lynne R., Yeap, Bu B., Allen, Naomi E., Key, Timothy J., Travis, Ruth C., The PRACTICAL Consortium, CRUK, BPC3, CAPS, PEGASUS, Watts, Eleanor L., Perez-Cornago, Aurora, Fensom, Georgina K., Smith-Byrne, Karl, Noor, Urwah, Andrews, Colm D., Gunter, Marc J., Holmes, Michael V., Martin, Richard M., Tsilidis, Konstantinos K., Albanes, Demetrius, Barricarte, Aurelio, Bueno-De-Mesquita, H. Bas, Cohn, Barbara A., Deschasaux-Tanguy, Melanie, Dimou, Niki L., Ferrucci, Luigi, Flicker, Leon, Freedman, Neal D., Giles, Graham G., Giovannucci, Edward L., Haiman, Christopher A., Hankey, Graham J., Holly, Jeffrey M. P., Huang, Jiaqi, Huang, Wen-Yi, Hurwitz, Lauren M., Kaaks, Rudolf, Kubo, Tatsuhiko, Le Marchand, Loic, Macinnis, Robert J., Männistö, Satu, Metter, E. Jeffrey, Mikami, Kazuya, Mucci, Lorelei A., Olsen, Anja W., Ozasa, Kotaro, Palli, Domenico, Penney, Kathryn L., Platz, Elizabeth A., Pollak, Michael N., Roobol, Monique J., Schaefer, Catherine A., Schenk, Jeannette M., Stattin, Pär, Tamakoshi, Akiko, Thysell, Elin, Tsai, Chiaojung Jillian, Touvier, Mathilde, Van Den Eeden, Stephen K., Weiderpass, Elisabete, Weinstein, Stephanie J., Wilkens, Lynne R., Yeap, Bu B., Allen, Naomi E., Key, Timothy J., Travis, Ruth C., and The PRACTICAL Consortium, CRUK, BPC3, CAPS, PEGASUS
- Abstract
Background: Previous studies had limited power to assess the associations of circulating insulin-like growth factors (IGFs) and IGF-binding proteins (IGFBPs) with clinically relevant prostate cancer as a primary endpoint, and the association of genetically predicted IGF-I with aggressive prostate cancer is not known. We aimed to investigate the associations of IGF-I, IGF-II, IGFBP-1, IGFBP-2 and IGFBP-3 concentrations with overall, aggressive and early-onset prostate cancer. Methods: Prospective analysis of biomarkers using the Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group dataset (up to 20 studies, 17 009 prostate cancer cases, including 2332 aggressive cases). Odds ratios (OR) and 95% confidence intervals (CI) for prostate cancer were estimated using conditional logistic regression. For IGF-I, two-sample Mendelian randomization (MR) analysis was undertaken using instruments identified using UK Biobank (158 444 men) and outcome data from PRACTICAL (up to 85 554 cases, including 15 167 aggressive cases). Additionally, we used colocalization to rule out confounding by linkage disequilibrium. Results: In observational analyses, IGF-I was positively associated with risks of overall (OR per 1 SD = 1.09: 95% CI 1.07, 1.11), aggressive (1.09: 1.03, 1.16) and possibly early-onset disease (1.11: 1.00, 1.24); associations were similar in MR analyses (OR per 1 SD = 1.07: 1.00, 1.15; 1.10: 1.01, 1.20; and 1.13; 0.98, 1.30, respectively). Colocalization also indicated a shared signal for IGF-I and prostate cancer (PP4: 99%). Men with higher IGF-II (1.06: 1.02, 1.11) and IGFBP-3 (1.08: 1.04, 1.11) had higher risks of overall prostate cancer, whereas higher IGFBP-1 was associated with a lower risk (0.95: 0.91, 0.99); these associations were attenuated following adjustment for IGF-I. Conclusions: These findings support the role of IGF-I in the development of prostate cancer, including for aggressive disease.
- Published
- 2023
- Full Text
- View/download PDF
115. The combined role of MRI prostate and prostate health index in improving detection of significant prostate cancer in a screening population of Chinese men
- Author
-
Chiu, Peter K.F., Lam, Thomas Y.T., Ng, Chi Fai, Teoh, Jeremy Y.C., Cho, Carmen C.M., Hung, Hiu Yee, Hong, Cindy, Roobol, Monique J., Chu, Winnie C.W., Wong, Samuel Y.S., Sung, Joseph J.Y., Chiu, Peter K.F., Lam, Thomas Y.T., Ng, Chi Fai, Teoh, Jeremy Y.C., Cho, Carmen C.M., Hung, Hiu Yee, Hong, Cindy, Roobol, Monique J., Chu, Winnie C.W., Wong, Samuel Y.S., and Sung, Joseph J.Y.
- Abstract
Using prostate-specific antigen (PSA) for prostate cancer (PCa) screening led to overinvestigation and overdiagnosis of indolent PCa. We aimed to investigate the value of prostate health index (PHI) and magnetic resonance imaging (MRI) prostate in an Asian PCa screening program. Men aged 50-75 years were prospectively recruited from a community-based PSA screening program. Men with PSA 4.0-10.0 ng ml -1 had PHI result analyzed. MRI prostate was offered to men with PSA 4.0-50.0 ng ml -1. A systematic prostate biopsy was offered to men with PSA 4.0-9.9 ng ml -1 and PHI ≥35, or PSA 10.0-50.0 ng ml -1. Additional targeted prostate biopsy was offered if they had PI-RADS score ≥3. Clinically significant PCa (csPCa) was defined as the International Society of Urological Pathology (ISUP) grade group (GG) ≥2 or ISUP GG 1 with involvement of ≥30% of total systematic cores. In total, 12.8% (196/1536) men had PSA ≥4.0 ng ml -1. Among 194 men with PSA 4.0-50.0 ng ml -1, 187 (96.4%) received MRI prostate. Among them, 28.3% (53/187) had PI-RADS ≥3 lesions. Moreover, 7.0% (107/1536) men were indicated for biopsy and 94.4% (101/107) men received biopsy. Among the men received biopsy, PCa, ISUP GG ≥2 PCa, and csPCa was diagnosed in 42 (41.6%), 24 (23.8%), and 34 (33.7%) men, respectively. Compared with PSA/PHI pathway in men with PSA 4.0-50.0 ng ml -1, additional MRI increased diagnoses of PCa, ISUP GG ≥2 PCa, and csPCa by 21.2% (from 33 to 40), 22.2% (from 18 to 22), and 18.5% (from 27 to 32), respectively. The benefit of additional MRI was only observed in PSA 4.0-10.0 ng ml -1, and the number of MRI needed to diagnose one additional ISUP GG ≥2 PCa was 20 in PHI ≥35 and 94 in PHI <35. Among them, 45.4% (89/196) men with PSA ≥4.0 ng ml -1 avoided unnecessary biopsy with the use of PHI and MRI. A screening algorithm with PSA, PHI, and MRI could effectively diagnose csPCa while reducing unnecessary biopsies. The benefit of MRI prostate was mainly observed in PSA 4.0-9.9 ng ml -1
- Published
- 2023
116. Navigating through the Controversies and Emerging Paradigms in Early Detection of Prostate Cancer:Bridging the Gap from Classic RCTs to Modern Population-Based Pilot Programs
- Author
-
Gómez Rivas, Juan, Leenen, Renée C.A., Venderbos, Lionne D.F., Helleman, Jozien, de la Parra, Irene, Vasilyeva, Vera, Moreno-Sierra, Jesús, Basu, Partha, Chandran, Arunah, van den Bergh, Roderick C.N., Collen, Sarah, Van Poppel, Hein, Roobol, Monique J., Beyer, Katharina, Gómez Rivas, Juan, Leenen, Renée C.A., Venderbos, Lionne D.F., Helleman, Jozien, de la Parra, Irene, Vasilyeva, Vera, Moreno-Sierra, Jesús, Basu, Partha, Chandran, Arunah, van den Bergh, Roderick C.N., Collen, Sarah, Van Poppel, Hein, Roobol, Monique J., and Beyer, Katharina
- Abstract
Over the last three decades, the European Randomized Study of Screening for Prostate Cancer (ERSPC) and the US-based Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening have steered the conversation around the early detection of prostate cancer. These two randomized trials assessed the effect of screening on prostate cancer disease-specific mortality. Elevated PSA levels were followed by a systematic sextant prostate biopsy. Standard repeat testing intervals were applied. After controversies from 2009 to 2016 due to contradicting results of the two trials, the results aligned in 2016 and showed that early PSA detection reduces prostate cancer-specific mortality. However, overdiagnosis rates of up to 50% were reported, and this sparked an intense debate on harms and benefits for almost 20 years. The balance between harms and benefits is highly debated and has initiated further research to investigate new ways of early detection. In the meantime, the knowledge and tools for the diagnostic algorithm improved. This is a continuously ongoing effort which focuses on individual risk-based screening algorithms that preserve the benefits of the purely PSA-based screening algorithms, while reducing the side effects. An important push towards investigating new techniques for early detection came from the European Commission on the 20th of September 2022. The European Commission published its updated recommendation to investigate prostate, lung, and gastric cancer early detection programs. This opened a new window of opportunity to move away from the trial setting to population-based early detection settings. With this review, we aim to review 30 years of historical evidence of prostate cancer screening, which led to the initiation of the 'The Prostate Cancer Awareness and Initiative for Screening in the European Union' (PRAISE-U) project, which aims to encourage the early detection and diagnosis of PCa through customized and risk-based screening programs.
- Published
- 2023
117. Lymphoceles after pelvic lymph node dissection during robot-assisted radical prostatectomy
- Author
-
Meenderink, Jonas J.L., Kroon, Lisa J., van der Slot, Margaretha A., Venderbos, Lionne D.F., van Leenders, Geert J.L.H., Roobol, Monique J., Busstra, Martijn B., Meenderink, Jonas J.L., Kroon, Lisa J., van der Slot, Margaretha A., Venderbos, Lionne D.F., van Leenders, Geert J.L.H., Roobol, Monique J., and Busstra, Martijn B.
- Abstract
Background: Lymphoceles, lymph fluid-filled collections within the body lacking epithelial lining, are a common complication after pelvic lymph node dissection (PLND) during robot-assisted radical prostatectomy (RARP). In this study, we investigate the incidence of imaging confirmed symptomatic lymphoceles (SLC) in a centralized high-volume operating centre and assess predictive factors and treatment.Methods: We retrospectively analysed the incidence, risk factors and treatment of a consecutive series of patients who underwent PLND during RARP between September 2018 and January 2021 in a specialised operation clinic. We compared baseline patients’ characteristics and pathological data between men who developed an SLC and those who did not. A multivariable model for the occurrence of an SLC was created using predetermined, clinically relevant variables to investigate predictive factors. Results: We analysed the records of 404 patients. The median follow-up length was 29 months. A total of 30 (7.4%) patients with an SLC were identified. The median time until SLC presentation was 12 weeks [interquartile range (IQR), 4–31 weeks], one-third of SLCs presented after 180 days. Percutaneous drainage was performed in 17 patients (57%). On multivariable analysis, only body mass index (BMI) significantly increased the odds of an SLC [per 5 odds ratio (OR) =1.7; 95% confidence interval (CI): 1.0–3.0, P=0.04]. Conclusions: SLCs present significant consequences, as more than half of patients with an SLC were treated with percutaneous drainage. Many patients presented later than the centralized surgeons’ postoperative follow-up, a drawback of centralized care. An increased BMI was a significant predictor for SLC.
- Published
- 2023
118. A literature review to understand health literacy in men with prostate cancer on active surveillance
- Author
-
Beyer, Katharina, Remmers, Sebastiaan, Van Hemelrijck, Mieke, Roobol, Monique J., Venderbos, Lionne D.F., Beyer, Katharina, Remmers, Sebastiaan, Van Hemelrijck, Mieke, Roobol, Monique J., and Venderbos, Lionne D.F.
- Abstract
Background and Objective: Active surveillance (AS) has been established as an important treatment option for patients with localised prostate cancer (PCa). Current evidence suggests that health literacy is an important facilitator or barrier to choosing and adhering to AS. We aim to understand how the level of health literacy has an impact on choosing and adhering to AS for PCa patients. Methods: We performed a narrative literature review in accordance with the Narrative Review guidelines through the MEDLINE online database via PubMed using two different search strategies to identify the relevant literature. We looked at literature until August 2022. A narrative synthesis was performed to identify if there is any evidence on how studies report health literacy as an outcome in the AS population and if there are any interventions targeting health literacy. Key Content and Findings: We identified 18 studies which looked at health literacy in the PCa context. Health literacy was measured in the context of comprehension of information of patients across PCa stages, decision making across PCa stages and quality of life (QoL) across PCa stages. Lower health literacy had a negative impact on the identified themes. Nine of the identified studies used validated health literacy measures. Interventions targeting health literacy have been used to improve health literacy with a positive impact across the patient journey. Conclusions: Health literacy plays an important role in enabling men to take an active part in their treatment journey. In this review, we presented how health literacy is measured and which interventions targeting health literacy are implemented across PCa. These examples of interventions targeting health literacy should be studied further and translated into the AS setting to improve treatment decision making and adherence to AS.
- Published
- 2023
119. How to follow the new EU Council recommendation and improve prostate cancer early detection:the Prostaforum 2022 declaration
- Author
-
Májek, Ondřej, Babjuk, Marek, Roobol, Monique J., Bratt, Ola, Van Poppel, Hendrik, Zachoval, Roman, Ferda, Jiří, Koudelková, Marcela, Ngo, Ondřej, Gregor, Jakub, Collen, Sarah, Hejduk, Karel, Dušek, Ladislav, Válek, Vlastimil, Májek, Ondřej, Babjuk, Marek, Roobol, Monique J., Bratt, Ola, Van Poppel, Hendrik, Zachoval, Roman, Ferda, Jiří, Koudelková, Marcela, Ngo, Ondřej, Gregor, Jakub, Collen, Sarah, Hejduk, Karel, Dušek, Ladislav, and Válek, Vlastimil
- Abstract
An updated Council of the EU recommendation on cancer screening was adopted in December 2022 during the Czech EU presidency. The recommendation included prostate cancer as a suitable target disease for organised screening, and invited countries to proceed with piloting and further research. To support further discussions and actions to promote early detection of prostate cancer, an international conference in November 2022 (Prostaforum 2022) resulted in a joint declaration. Here we describe the EU policy background, summarise the preparation of the declaration and the key underlying evidence and expert recommendations, and report the text of the declaration. The declaration summarises the striking inequalities in prostate cancer burden in Europe and calls on all stakeholders to consider and support concrete steps for advancement of organised early detection of prostate cancer. Our aim is to request endorsement of the text and potential initiation of practical actions by all stakeholders to support the aims of the declaration. Patient summary: Prostate cancer is among the most frequent cancers and is one of the most common causes of cancer death among men. The European Union has recommended new pilot programmes for prostate cancer screening. The Prostaforum 2022 declaration invites all stakeholders to support this new recommendation with specific steps.
- Published
- 2023
120. Active Surveillance for Prostate Cancer:Past, Current, and Future Trends
- Author
-
de Vos, Ivo I., Luiting, Henk B., Roobol, Monique J., de Vos, Ivo I., Luiting, Henk B., and Roobol, Monique J.
- Abstract
In response to the rising incidence of indolent, low-risk prostate cancer (PCa) due to increased prostate-specific antigen (PSA) screening in the 1990s, active surveillance (AS) emerged as a treatment modality to combat overtreatment by delaying or avoiding unnecessary definitive treatment and its associated morbidity. AS consists of regular monitoring of PSA levels, digital rectal exams, medical imaging, and prostate biopsies, so that definitive treatment is only offered when deemed necessary. This paper provides a narrative review of the evolution of AS since its inception and an overview of its current landscape and challenges. Although AS was initially only performed in a study setting, numerous studies have provided evidence for the safety and efficacy of AS which has led guidelines to recommend it as a treatment option for patients with low-risk PCa. For intermediate-risk disease, AS appears to be a viable option for those with favourable clinical characteristics. Over the years, the inclusion criteria, follow-up schedule and triggers for definitive treatment have evolved based on the results of various large AS cohorts. Given the burdensome nature of repeat biopsies, risk-based dynamic monitoring may further reduce overtreatment by avoiding repeat biopsies in selected patients.
- Published
- 2023
121. Relationship Between Baseline Prostate-specific Antigen on Cancer Detection and Prostate Cancer Death:Long-term Follow-up from the European Randomized Study of Screening for Prostate Cancer
- Author
-
Remmers, Sebastiaan, Bangma, Chris H., Godtman, Rebecka A., Carlsson, Sigrid V., Auvinen, Anssi, Tammela, Teuvo L.J., Denis, Louis J., Nelen, Vera, Villers, Arnauld, Rebillard, Xavier, Kwiatkowski, Maciej, Recker, Franz, Wyler, Stephen, Zappa, Marco, Puliti, Donella, Gorini, Giuseppe, Paez, Alvaro, Lujan, Marcos, Nieboer, Daan, Schröder, Fritz H., Roobol, Monique J., Remmers, Sebastiaan, Bangma, Chris H., Godtman, Rebecka A., Carlsson, Sigrid V., Auvinen, Anssi, Tammela, Teuvo L.J., Denis, Louis J., Nelen, Vera, Villers, Arnauld, Rebillard, Xavier, Kwiatkowski, Maciej, Recker, Franz, Wyler, Stephen, Zappa, Marco, Puliti, Donella, Gorini, Giuseppe, Paez, Alvaro, Lujan, Marcos, Nieboer, Daan, Schröder, Fritz H., and Roobol, Monique J.
- Abstract
Background: The European Association of Urology guidelines recommend a risk-based strategy for prostate cancer screening based on the first prostate-specific antigen (PSA) level and age. Objective: To analyze the impact of the first PSA level on prostate cancer (PCa) detection and PCa-specific mortality (PCSM) in a population-based screening trial (repeat screening every 2–4 yr). Design, setting, and participants: We evaluated 25 589 men aged 55–59 yr, 16 898 men aged 60–64 yr, and 12 936 men aged 65–69 yr who attended at least one screening visit in the European Randomized Study of Screening for Prostate Cancer (ERSPC) trial (screening arm: repeat PSA testing every 2–4 yr and biopsy in cases with elevated PSA; control arm: no active screening offered) during 16-yr follow-up (FU). Outcome measurements and statistical analysis: We assessed the actuarial probability for any PCa and for clinically significant (cs)PCa (Gleason ≥7). Cox proportional-hazards regression was performed to assess whether the association between baseline PSA and PCSM was comparable for all age groups. A Lorenz curve was computed to assess the association between baseline PSA and PCSM for men aged 60–61 yr. Results and limitations: The overall actuarial probability at 16 yr ranged from 12% to 16% for any PCa and from 3.7% to 5.7% for csPCa across the age groups. The actuarial probability of csPCa at 16 yr ranged from 1.2–1.5% for men with PSA <1.0 ng/ml to 13.3–13.8% for men with PSA ≥3.0 ng/ml. The association between baseline PSA and PCSM differed marginally among the three age groups. A Lorenz curve for men aged 60–61 yr showed that 92% of lethal PCa cases occurred among those with PSA above the median (1.21 ng/ml). In addition, for men initially screened at age 60–61 yr with baseline PSA <2 ng/ml, further continuation of screening is unlikely to be beneficial after the age of 68–70 yr if PSA is still <2 ng/ml. No case of PCSM emerged in the sub
- Published
- 2023
122. A Detailed Evaluation of the Effect of Prostate-specific Antigen–based Screening on Morbidity and Mortality of Prostate Cancer:21-year Follow-up Results of the Rotterdam Section of the European Randomised Study of Screening for Prostate Cancer
- Author
-
de Vos, Ivo I., Meertens, Annick, Hogenhout, Renée, Remmers, Sebastiaan, Roobol, Monique J., de Vos, Ivo I., Meertens, Annick, Hogenhout, Renée, Remmers, Sebastiaan, and Roobol, Monique J.
- Abstract
Background: Considering the long natural history of prostate cancer (PCa), long-term results of the European Randomised Study of Screening for PCa (ERSPC) are crucial. Objective: To provide an update on the effect of prostate-specific antigen (PSA)-based screening on PCa-specific mortality (PCSM), metastatic disease, and overdiagnosis in the Dutch arm of the ERSPC. Design, setting, and participants: Between 1993 and 2000, a total of 42 376 men, aged 55–74 yr, were randomised to a screening or a control arm. The main analysis was performed with men aged 55–69 yr (n = 34 831). Men in the screening arm were offered PSA-based screening with an interval of 4 yr. Outcome measurements and statistical analysis: Intention-to-screen analyses with Poisson regression were used to calculate rate ratios (RRs) of PCSM and metastatic PCa. Results and limitations: After a median follow-up of 21 yr, the RR of PCSM was 0.73 (95% confidence interval [CI]: 0.61–0.88) favouring screening. The numbers of men needed to invite (NNI) and needed to diagnose (NND) to prevent one PCa death were 246 and 14, respectively. For metastatic PCa, the RR was 0.67 (95% CI: 0.58–0.78) favouring screening. The NNI and NND to prevent one metastasis were 121 and 7, respectively. No statistical difference in PCSM (RR of 1.18 [95% CI: 0.87–1.62]) was observed in men aged ≥70 yr at the time of randomisation. In the screening arm, higher rates of PCSM and metastatic disease were observed in men who were screened only once and in a selected group of men above the screening age cut-off of 74 yr. Conclusions: The current analysis illustrates that with a follow-up of 21 yr, both absolute metastasis and mortality reduction continue to increase, resulting in a more favourable harm-benefit ratio than demonstrated previously. These data do not support starting screening at the age of 70–74 yr and show that repeated screening is essential. Patient summary: Prostate-specific antigen–based prostate cancer screening red
- Published
- 2023
123. The Patient Journey from Randomization to Detection of Prostate Cancer and Death:Results from ERSPC Rotterdam
- Author
-
Remmers, Sebastiaan, Nieboer, Daan, Roobol, Monique J., Remmers, Sebastiaan, Nieboer, Daan, and Roobol, Monique J.
- Abstract
Background: The ERSPC study has demonstrated that prostate-specific antigen (PSA)-based screening results in a relative increase in diagnosis of (low-risk) prostate cancer (PCa) and a reduction in metastatic disease and PCa mortality. Objective: To evaluate the burden of PCa among men randomized to active screening compared to those in the control arm in ERSPC Rotterdam. Design, setting, and participants: We analyzed data for participants in the Dutch section of the ERSPC, including 21 169 men randomized to the screening arm and 21 136 randomized to the control arm. Men in the screening arm were invited for PSA-based screening every 4 yr, and transrectal ultrasound–guided prostate biopsy was recommended for those with PSA ≥3.0 ng/ml. Outcome measurements and statistical analysis: We analyzed detailed follow-up and mortality data up to January 1, 2019, to a maximum of 21 yr, using multistate models. Results and limitations: At 21 yr, 3046 men (14%) had been diagnosed with nonmetastatic PCa and 161 (0.76%) with metastatic PCa in the screening arm. In the control arm, 1698 men (8.0%) had been diagnosed with nonmetastatic PCa and 346 (1.6%) with metastatic PCa. In comparison to the control arm, men in the screening arm were diagnosed with PCa almost 1 yr earlier and if diagnosed with nonmetastatic PCa lived on average for almost 1 yr longer without disease progression. Among those who experienced biochemical recurrence (18–19% after nonmetastatic PCa), progression to metastatic disease or death was quicker in the control arm: men in the screening arm lived for 7.17 yr without progression, while the progression-free interval was only 1.59 yr for men in the control arm over a 10-yr time period. Among those who experienced metastatic disease, men in both study arms lived for 5 yr over a 10-yr time period. Conclusions: PCa diagnosis was earlier after study entry for men in the PSA-based screening arm. However, disease progression was not as fast in the screening arm as i
- Published
- 2023
124. Prostate cancer risk assessment by the primary care physician and urologist:transabdominal- versus transrectal ultrasound prostate volume-based use of the Rotterdam Prostate Cancer Risk Calculator
- Author
-
de Vos, Ivo I., Drost, Frank Jan H., Bokhorst, Leonard P., Alberts, Arnout R., van Gelder, Martine, Herman, Erik M., Boswinkel, Wouter D., Bangma, Chris H., Roobol, Monique J., de Vos, Ivo I., Drost, Frank Jan H., Bokhorst, Leonard P., Alberts, Arnout R., van Gelder, Martine, Herman, Erik M., Boswinkel, Wouter D., Bangma, Chris H., and Roobol, Monique J.
- Abstract
Background: Our objective was to assess the accuracy of transabdominal ultrasound (TAUS) measured prostate volume in the primary care setting with transrectal ultrasound (TRUS) measured prostate volume by the urologist as the reference test. Furthermore, our objective was to assess whether risk-stratification using TAUS prostate volume by the primary care physician could reduce unnecessary referrals to the urologist. Methods: Men in two Dutch primary care offices with a prostate cancer (PCa) screening request received a digital rectal examination (DRE), prostate specific-antigen (PSA), and TAUS prostate volume measurement by the general practitioner, followed by Rotterdam Prostate Cancer Risk Calculator (RPCRC) risk assessment. The examination was repeated by a urologist using TRUS. A prostate biopsy was performed in case of a RPCRC positive biopsy advice. A non-inferiority analysis was performed comparing TAUS and TRUS prostate volume differences. A risk-based referral strategy using TAUS and the RPCRC in the primary care setting was compared with the standard referral strategy based on PSA (≥3 ng/mL) and DRE. Results: A total of 105 men were included with a median PSA of 1.9 ng/mL. The mean prostate volumes measured by TAUS and TRUS were 55 and 45 mL, respectively. The mean overestimation of the prostate volume by TAUS as compared to the reference test was 9.9 mL (95% CI: 5.9–13.8). According to Dutch standard practice, 41 out of 105 (39%) men would have been referred to the urologist. Stratification in primary care based on the RPCRC using TAUS prostate volume would have avoided 29 out of the 41 (71%) referrals, at the expense of non-referral of 5 out of 11 (45%) men with a biopsy indication, according to the urologist. Conclusions: RPCRC-based risk stratification in primary care using TAUS prostate volume measurement is feasible and may prevent unnecessary referrals to the urologist and reduce costs. The accuracy of the risk assessment with TAUS might be impr
- Published
- 2023
125. Mapping European Association of Urology Guideline Practice Across Europe:An Audit of Androgen Deprivation Therapy Use Before Prostate Cancer Surgery in 6598 Cases in 187 Hospitals Across 31 European Countries
- Author
-
MacLennan, Steven, Azevedo, Nuno, Duncan, Eilidh, Dunsmore, Jennifer, Fullwood, Louise, Lumen, Nicolaas, Plass, Karin, Ribal, Maria J., Roobol, Monique J., Nieboer, Daan, Schouten, Natasha, Skolarus, Ted A., Smith, Emma Jane, N'Dow, James, Mottet, Nicolas, Briganti, Alberto, MacLennan, Steven, Azevedo, Nuno, Duncan, Eilidh, Dunsmore, Jennifer, Fullwood, Louise, Lumen, Nicolaas, Plass, Karin, Ribal, Maria J., Roobol, Monique J., Nieboer, Daan, Schouten, Natasha, Skolarus, Ted A., Smith, Emma Jane, N'Dow, James, Mottet, Nicolas, and Briganti, Alberto
- Abstract
Background: Evidence-practice gaps exist in urology. We previously surveyed European Association of Urology (EAU) guidelines for strong recommendations underpinned by high-certainty evidence that impact patient experience for which practice variations were suspected. The recommendation “Do not offer neoadjuvant androgen deprivation therapy (ADT) before surgery for patients with prostate cancer” was prioritised for further investigation. ADT before surgery is neither clinically effective nor cost effective and has serious side effects. The first step in improving implementation problems is to understand their extent. A clear picture of practice regarding ADT before surgery across Europe is not available. Objective: To assess current ADT use before prostate cancer surgery in Europe. Design, setting, and participants: This was an observational cross-sectional study. We retrospectively audited recent ADT practices in a multicentre international setting. We used nonprobability purposive sampling, aiming for breadth in terms of low- versus high-volume, academic, versus community and public versus private centres. Outcome measurements and statistical analysis: Our primary outcome was adherence to the ADT recommendation. Descriptive statistics and a multilevel model were used to investigate differences between countries across different factors (volume, centre type, and funding type). Subgroup analyses were performed for patients with low, intermediate, and high risk, and for those with locally advanced prostate cancer. We also collected reasons for nonadherence. Results and limitations: We included 6598 patients with prostate cancer from 187 hospitals in 31 countries from January 1, 2017 to May 1, 2020. Overall, nonadherence was 2%, (range 0–32%). Most of the variability was found in the high-risk subgroup, for which nonadherence was 4% (range 0–43%). Reasons for nonadherence included attempts to improve oncological outcomes or preoperative tumour parameters; attempts t
- Published
- 2023
126. Shifting risk-stratified early prostate cancer detection to a primary healthcare setting
- Author
-
Hogenhout, Renée, Osses, Daniël F., Alberts, Arnout R., Buizer-Rijksen, Hanne G., Remmers, Sebastiaan, Roobol, Monique J., Hogenhout, Renée, Osses, Daniël F., Alberts, Arnout R., Buizer-Rijksen, Hanne G., Remmers, Sebastiaan, and Roobol, Monique J.
- Abstract
Objective: To evaluate the feasibility of multivariable risk stratification for early prostate cancer (PCa) detection in a primary healthcare diagnostic facility with regard to its effects on the referral rate and subsequent PCa diagnoses compared to a PSA threshold of 3.0 ng/mL as the current referral indicator. Patients and Methods: In 2014, the Erasmus MC Cancer Institute and the primary healthcare diagnostic facility STAR-SHL (located in Rotterdam city centre) initiated this observational study, in which general practitioners (GPs) could refer men who wished to undergo PCa screening to STAR-SHL for consultation by specially trained personnel. Referral recommendations to secondary healthcare were based on the outcome of application of the Rotterdam Prostate Cancer Risk Calculator (RPCRC) and were compared to the current Dutch GPs' PSA referral threshold of 3.0 ng/mL. For data collection on PCa diagnoses, the study cohort was linked to the Dutch nationwide pathology databank (PALGA). Results: Between January 2014 and February 2021, 507 men were referred for consultation and in 495 men prostate-specific antigen (PSA) was tested. The median (interquartile range) follow-up from consultation to PALGA linkage was 43 (25–65) months. In total, 279 men (56%) had a PSA level ≥3.0 ng/mL, of whom 68% (95% confidence interval [95% CI] 63–74) were considered at low risk according to the RPCRC. Within 1 year after consultation, one of these men (0.52%; 95% CI 0.092–2.9) was diagnosed with clinically significant (cs)PCa (i.e., International Society of Urological Pathology Grade Group ≥2). Thereafter, another four (2.1%; 95% CI 0.82–5.3) low-risk men were diagnosed with csPCa. Of the high-risk men who were biopsied within 1 year after consultation (n = 61), 77% (95% CI 65–86) were diagnosed with PCa and 49% (95% CI 37–61) with csPCa. Conclusion: In a primary healthcare diagnostic facility, the RPCRC could reduce up to 68% of referrals to secondary healthca
- Published
- 2023
127. Interaction of MRI and active surveillance in prostate cancer:Time to re-evaluate the active surveillance inclusion criteria
- Author
-
Venderbos, Lionne DF, Luiting, Henk, Hogenhout, Renée, Roobol, Monique J., Venderbos, Lionne DF, Luiting, Henk, Hogenhout, Renée, and Roobol, Monique J.
- Abstract
Currently available data from long-running single- and multi-center active surveillance (AS) studies show that AS has excellent cancer-specific survival rates. For AS to be effective the ‘right’ patients should be selected for which up until 5-to-10 years ago systematic prostate biopsies were used. Because the systematic prostate strategy relies on sampling efficiency for the detection of prostate cancer (PCa), it is subject to sampling error. Due to this sampling error, many of the Gleason 3+3 PCas that were included on AS in the early days and were classified as low-risk, may in fact have had a higher Gleason score. Subsequently, AS-criteria were more strict to overcome or limit the number of men missing the potential window of curability in case their tumor would be reclassified. Five to ten years ago the prostate biopsy landscape changed drastically by the addition of magnetic resonance imaging (MRI) into the diagnostic PCa-care pathway, which has by now trickled down into the EAU guidelines. At the moment, the EAU guidelines recommend performing a (multi-parametric) MRI before prostate biopsy and combine systematic and targeted prostate biopsy when the MRI is positive (i.e. PIRADS ≥3). So because of the introduction of the MRI into the diagnostic PCa-care pathway, literature is showing that more Gleason 3+4 PCas are being diagnosed. But can it not be that the inclusion of MRI into the diagnostic PCa-care pathway causes risk inflation, resulting in men earlier eligible for AS, now being labelled ineligible for AS? Would it not be possible to include these current Gleason 3+4 PCas on AS? The authors hypothesize that the improved accuracy that comes with the introduction of MRI into the diagnostic PCa-care pathway permits to widen both the AS-inclusion and follow-up criteria. Maintaining our inclusion criteria for AS from the systematic biopsy era will unnecessarily and undesirably expose patients to the increased risk of overtreatment. The evidence behind the
- Published
- 2023
128. Research protocol to identify progression and death amongst patients with metastatic hormone-sensitive prostate cancer treated with available treatments: PIONEER IMI's 'big data for better outcomes' program
- Author
-
MS Urologische Oncologie, Cancer, Gomez Rivas, Juan, Nicoletti, Rossella, Ibáñez, Laura, Steinbeisser, Carl, de Meulder, Bertrand, Golozar, Asieh, Axelsson, Susan Evans, Snijder, Robert, Bjartell, Anders, Cornford, Philip, Van Hemelrijck, Mieke, Beyer, Katharina, Willemse, Peter-Paul, Murtola, Teemu, Roobol, Monique J, Moreno-Sierra, Jesús, Campi, Riccardo, Gacci, Mauro, Mottet, Nicolas, Merseburger, Axel, Ndow, James, MS Urologische Oncologie, Cancer, Gomez Rivas, Juan, Nicoletti, Rossella, Ibáñez, Laura, Steinbeisser, Carl, de Meulder, Bertrand, Golozar, Asieh, Axelsson, Susan Evans, Snijder, Robert, Bjartell, Anders, Cornford, Philip, Van Hemelrijck, Mieke, Beyer, Katharina, Willemse, Peter-Paul, Murtola, Teemu, Roobol, Monique J, Moreno-Sierra, Jesús, Campi, Riccardo, Gacci, Mauro, Mottet, Nicolas, Merseburger, Axel, and Ndow, James
- Published
- 2023
129. Mapping European Association of Urology Guideline Practice Across Europe: An Audit of Androgen Deprivation Therapy Use Before Prostate Cancer Surgery in 6598 Cases in 187 Hospitals Across 31 European Countries
- Author
-
MacLennan, Steven, Azevedo, Nuno, Duncan, Eilidh, Dunsmore, Jennifer, Fullwood, Louise, Lumen, Nicolaas, Plass, Karin, Ribal, Maria J, Roobol, Monique J, Nieboer, Daan, Schouten, Natasha, Skolarus, Ted A, Smith, Emma Jane, N'Dow, James, Mottet, Nicolas, Briganti, Alberto, et al, Pan-European National Urological Society IMAGINE Collaborative, Eberli, Daniel; https://orcid.org/0000-0001-8866-8010, Oechslin, Pascal, MacLennan, Steven, Azevedo, Nuno, Duncan, Eilidh, Dunsmore, Jennifer, Fullwood, Louise, Lumen, Nicolaas, Plass, Karin, Ribal, Maria J, Roobol, Monique J, Nieboer, Daan, Schouten, Natasha, Skolarus, Ted A, Smith, Emma Jane, N'Dow, James, Mottet, Nicolas, Briganti, Alberto, et al, Pan-European National Urological Society IMAGINE Collaborative, Eberli, Daniel; https://orcid.org/0000-0001-8866-8010, and Oechslin, Pascal
- Abstract
BACKGROUND Evidence-practice gaps exist in urology. We previously surveyed European Association of Urology (EAU) guidelines for strong recommendations underpinned by high-certainty evidence that impact patient experience for which practice variations were suspected. The recommendation "Do not offer neoadjuvant androgen deprivation therapy (ADT) before surgery for patients with prostate cancer" was prioritised for further investigation. ADT before surgery is neither clinically effective nor cost effective and has serious side effects. The first step in improving implementation problems is to understand their extent. A clear picture of practice regarding ADT before surgery across Europe is not available. OBJECTIVE To assess current ADT use before prostate cancer surgery in Europe. DESIGN, SETTING, AND PARTICIPANTS This was an observational cross-sectional study. We retrospectively audited recent ADT practices in a multicentre international setting. We used nonprobability purposive sampling, aiming for breadth in terms of low- versus high-volume, academic, versus community and public versus private centres. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS Our primary outcome was adherence to the ADT recommendation. Descriptive statistics and a multilevel model were used to investigate differences between countries across different factors (volume, centre type, and funding type). Subgroup analyses were performed for patients with low, intermediate, and high risk, and for those with locally advanced prostate cancer. We also collected reasons for nonadherence. RESULTS AND LIMITATIONS We included 6598 patients with prostate cancer from 187 hospitals in 31 countries from January 1, 2017 to May 1, 2020. Overall, nonadherence was 2%, (range 0-32%). Most of the variability was found in the high-risk subgroup, for which nonadherence was 4% (range 0-43%). Reasons for nonadherence included attempts to improve oncological outcomes or preoperative tumour parameters; attempts to contro
- Published
- 2023
130. Prostate cancer outcomes of men with biopsy Gleason score 6 and 7 without cribriform or intraductal carcinoma
- Author
-
Kweldam, Charlotte F., Kümmerlin, Intan P., Nieboer, Daan, Verhoef, Esther I., Steyerberg, Ewout W., Incrocci, Luca, Bangma, Chris H., van der Kwast, Theodorus H., Roobol, Monique J., and van Leenders, Geert J.
- Published
- 2016
- Full Text
- View/download PDF
131. Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy
- Author
-
Kweldam, Charlotte F, Kümmerlin, Intan P, Nieboer, Daan, Verhoef, Esther I, Steyerberg, Ewout W, van der Kwast, Theodorus H, Roobol, Monique J, and van Leenders, Geert J
- Published
- 2016
- Full Text
- View/download PDF
132. Evaluating Approaches for Constructing Polygenic Risk Scores for Prostate Cancer in Men of African and European Ancestry
- Author
-
Darst, Burcu F., Shen, Jiayi, Madduri, Ravi K., Rodriguez, Alexis A., Xiao, Yukai, Sheng, Xin, Saunders, Edward J., Dadaev, Tokhir, Brook, Mark N., Hoffmann, Thomas J., Muir, Kenneth, Wan, Peggy, Marchand, Loic Le, Wilkens, Lynne, Wang, Ying, Schleutker, Johanna, MacInnis, Robert J., Cybulski, Cezary, Neal, David E., G. Nordestgaard, Børge, Nielsen, Sune F., Batra, Jyotsna, Clements, Judith A., Grönberg, Henrik, Pashayan, Nora, Travis, Ruth C., Park, Jong Y., Albanes, Demetrius, Weinstein, Stephanie, Mucci, Lorelei A., Hunter, David J., Penney, Kathryn L., Tangen, Catherine M., Hamilton, Robert J., Parent, Marie-Élise, Stanford, Janet L., Koutros, Stella, Wolk, Alicja, Sørensen, Karina D., Blot, William J., Yeboah, Edward D., Mensah, James E., Lu, Yong-Jie, Schaid, Daniel J., Thibodeau, Stephen N., West, Catharine M., Maier, Christiane, Kibel, Adam S., Cancel-Tassin, Géraldine, Menegaux, Florence, John, Esther M., Grindedal, Eli Marie, Khaw, Kay-Tee, Ingles, Sue A., Vega, Ana, Rosenstein, Barry S., Teixeira, Manuel R., Kogevinas, Manolis, Cannon-Albright, Lisa, Huff, Chad, Multigner, Luc, Kaneva, Radka, Leach, Robin J., Brenner, Hermann, Hsing, Ann W., Kittles, Rick A., Murphy, Adam B., Logothetis, Christopher J., Neuhausen, Susan L., Isaacs, William B., Nemesure, Barbara, Hennis, Anselm J., Carpten, John, Pandha, Hardev, De Ruyck, Kim, Xu, Jianfeng, Razack, Azad, Teo, Soo-Hwang, Newcomb, Lisa F., Fowke, Jay H., Neslund-Dudas, Christine, Rybicki, Benjamin A., Gamulin, Marija, Usmani, Nawaid, Claessens, Frank, Gago-Dominguez, Manuela, Castelao, Jose Esteban, Townsend, Paul A., Crawford, Dana C., Petrovics, Gyorgy, Casey, Graham, Roobol, Monique J., Hu, Jennifer F., Berndt, Sonja I., Van Den Eeden, Stephen K., Easton, Douglas F., Chanock, Stephen J., Cook, Michael B., Wiklund, Fredrik, Witte, John S., Eeles, Rosalind A., Kote-Jarai, Zsofia, Watya, Stephen, Gaziano, John M., Justice, Amy C., Conti, David V., and Haiman, Christopher A.
- Subjects
Article - Abstract
Genome-wide polygenic risk scores (GW-PRS) have been reported to have better predictive ability than PRS based on genome-wide significance thresholds across numerous traits. We compared the predictive ability of several GW-PRS approaches to a recently developed PRS of 269 established prostate cancer risk variants from multi-ancestry GWAS and fine-mapping studies (PRS (269) ). GW-PRS models were trained using a large and diverse prostate cancer GWAS of 107,247 cases and 127,006 controls used to develop the multi-ancestry PRS (269) . Resulting models were independently tested in 1,586 cases and 1,047 controls of African ancestry from the California/Uganda Study and 8,046 cases and 191,825 controls of European ancestry from the UK Biobank and further validated in 13,643 cases and 210,214 controls of European ancestry and 6,353 cases and 53,362 controls of African ancestry from the Million Veteran Program. In the testing data, the best performing GW-PRS approach had AUCs of 0.656 (95% CI=0.635-0.677) in African and 0.844 (95% CI=0.840-0.848) in European ancestry men and corresponding prostate cancer OR of 1.83 (95% CI=1.67-2.00) and 2.19 (95% CI=2.14-2.25), respectively, for each SD unit increase in the GW-PRS. However, compared to the GW-PRS, in African and European ancestry men, the PRS (269) had larger or similar AUCs (AUC=0.679, 95% CI=0.659-0.700 and AUC=0.845, 95% CI=0.841-0.849, respectively) and comparable prostate cancer OR (OR=2.05, 95% CI=1.87-2.26 and OR=2.21, 95% CI=2.16-2.26, respectively). Findings were similar in the validation data. This investigation suggests that current GW-PRS approaches may not improve the ability to predict prostate cancer risk compared to the multi-ancestry PRS (269) constructed with fine-mapping.
- Published
- 2023
133. Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction
- Author
-
Conti, David V., Darst, Burcu F., Moss, Lilit C., Saunders, Edward J., Sheng, Xin, Chou, Alisha, Schumacher, Fredrick R., Olama, Ali Amin Al, Benlloch, Sara, Dadaev, Tokhir, Brook, Mark N., Sahimi, Ali, Hoffmann, Thomas J., Takahashi, Atushi, Matsuda, Koichi, Momozawa, Yukihide, Fujita, Masashi, Muir, Kenneth, Lophatananon, Artitaya, Wan, Peggy, Le Marchand, Loic, Wilkens, Lynne R., Stevens, Victoria L., Gapstur, Susan M., Carter, Brian D., Schleutker, Johanna, Tammela, Teuvo L. J., Sipeky, Csilla, Auvinen, Anssi, Giles, Graham G., Southey, Melissa C., MacInnis, Robert J., Cybulski, Cezary, Wokołorczyk, Dominika, Lubiński, Jan, Neal, David E., Donovan, Jenny L., Hamdy, Freddie C., Martin, Richard M., Nordestgaard, Børge G., Nielsen, Sune F., Weischer, Maren, Bojesen, Stig E., Røder, Martin Andreas, Iversen, Peter, Batra, Jyotsna, Chambers, Suzanne, Moya, Leire, Horvath, Lisa, Clements, Judith A., Tilley, Wayne, Risbridger, Gail P., Gronberg, Henrik, Aly, Markus, Szulkin, Robert, Eklund, Martin, Nordström, Tobias, Pashayan, Nora, Dunning, Alison M., Ghoussaini, Maya, Travis, Ruth C., Key, Tim J., Riboli, Elio, Park, Jong Y., Sellers, Thomas A., Lin, Hui-Yi, Albanes, Demetrius, Weinstein, Stephanie J., Mucci, Lorelei A., Giovannucci, Edward, Lindstrom, Sara, Kraft, Peter, Hunter, David J., Penney, Kathryn L., Turman, Constance, Tangen, Catherine M., Goodman, Phyllis J., Thompson, Jr., Ian M., Hamilton, Robert J., Fleshner, Neil E., Finelli, Antonio, Parent, Marie-Élise, Stanford, Janet L., Ostrander, Elaine A., Geybels, Milan S., Koutros, Stella, Freeman, Laura E. Beane, Stampfer, Meir, Wolk, Alicja, Håkansson, Niclas, Andriole, Gerald L., Hoover, Robert N., Machiela, Mitchell J., Sørensen, Karina Dalsgaard, Borre, Michael, Blot, William J., Zheng, Wei, Yeboah, Edward D., Mensah, James E., Lu, Yong-Jie, Zhang, Hong-Wei, Feng, Ninghan, Mao, Xueying, Wu, Yudong, Zhao, Shan-Chao, Sun, Zan, Thibodeau, Stephen N., McDonnell, Shannon K., Schaid, Daniel J., West, Catharine M. L., Burnet, Neil, Barnett, Gill, Maier, Christiane, Schnoeller, Thomas, Luedeke, Manuel, Kibel, Adam S., Drake, Bettina F., Cussenot, Olivier, Cancel-Tassin, Géraldine, Menegaux, Florence, Truong, Thérèse, Koudou, Yves Akoli, John, Esther M., Grindedal, Eli Marie, Maehle, Lovise, Khaw, Kay-Tee, Ingles, Sue A., Stern, Mariana C., Vega, Ana, Gómez-Caamaño, Antonio, Fachal, Laura, Rosenstein, Barry S., Kerns, Sarah L., Ostrer, Harry, Teixeira, Manuel R., Paulo, Paula, Brandão, Andreia, Watya, Stephen, Lubwama, Alexander, Bensen, Jeannette T., Fontham, Elizabeth T. H., Mohler, James, Taylor, Jack A., Kogevinas, Manolis, Llorca, Javier, Castaño-Vinyals, Gemma, Cannon-Albright, Lisa, Teerlink, Craig C., Huff, Chad D., Strom, Sara S., Multigner, Luc, Blanchet, Pascal, Brureau, Laurent, Kaneva, Radka, Slavov, Chavdar, Mitev, Vanio, Leach, Robin J., Weaver, Brandi, Brenner, Hermann, Cuk, Katarina, Holleczek, Bernd, Saum, Kai-Uwe, Klein, Eric A., Hsing, Ann W., Kittles, Rick A., Murphy, Adam B., Logothetis, Christopher J., Kim, Jeri, Neuhausen, Susan L., Steele, Linda, Ding, Yuan Chun, Isaacs, William B., Nemesure, Barbara, Hennis, Anselm J. M., Carpten, John, Pandha, Hardev, Michael, Agnieszka, De Ruyck, Kim, De Meerleer, Gert, Ost, Piet, Xu, Jianfeng, Razack, Azad, Lim, Jasmine, Teo, Soo-Hwang, Newcomb, Lisa F., Lin, Daniel W., Fowke, Jay H., Neslund-Dudas, Christine, Rybicki, Benjamin A., Gamulin, Marija, Lessel, Davor, Kulis, Tomislav, Usmani, Nawaid, Singhal, Sandeep, Parliament, Matthew, Claessens, Frank, Joniau, Steven, Van den Broeck, Thomas, Gago-Dominguez, Manuela, Castelao, Jose Esteban, Martinez, Maria Elena, Larkin, Samantha, Townsend, Paul A., Aukim-Hastie, Claire, Bush, William S., Aldrich, Melinda C., Crawford, Dana C., Srivastava, Shiv, Cullen, Jennifer C., Petrovics, Gyorgy, Casey, Graham, Roobol, Monique J., Jenster, Guido, van Schaik, Ron H. N., Hu, Jennifer J., Sanderson, Maureen, Varma, Rohit, McKean-Cowdin, Roberta, Torres, Mina, Mancuso, Nicholas, Berndt, Sonja I., Van Den Eeden, Stephen K., Easton, Douglas F., Chanock, Stephen J., Cook, Michael B., Wiklund, Fredrik, Nakagawa, Hidewaki, Witte, John S., Eeles, Rosalind A., Kote-Jarai, Zsofia, and Haiman, Christopher A.
- Published
- 2021
- Full Text
- View/download PDF
134. Early detection and screening for prostate cancer
- Author
-
van Leeuwen, Pim J., primary, Roobol, Monique J., additional, and Stricker, Phillip D., additional
- Published
- 2018
- Full Text
- View/download PDF
135. Publisher Correction: Shared heritability and functional enrichment across six solid cancers
- Author
-
Jiang, Xia, Finucane, Hilary K., Schumacher, Fredrick R., Schmit, Stephanie L., Tyrer, Jonathan P., Han, Younghun, Michailidou, Kyriaki, Lesseur, Corina, Kuchenbaecker, Karoline B., Dennis, Joe, Conti, David V., Casey, Graham, Gaudet, Mia M., Huyghe, Jeroen R., Albanes, Demetrius, Aldrich, Melinda C., Andrew, Angeline S., Andrulis, Irene L., Anton-Culver, Hoda, Antoniou, Antonis C., Antonenkova, Natalia N., Arnold, Susanne M., Aronson, Kristan J., Arun, Banu K., Bandera, Elisa V., Barkardottir, Rosa B., Barnes, Daniel R., Batra, Jyotsna, Beckmann, Matthias W., Benitez, Javier, Benlloch, Sara, Berchuck, Andrew, Berndt, Sonja I., Bickeböller, Heike, Bien, Stephanie A., Blomqvist, Carl, Boccia, Stefania, Bogdanova, Natalia V., Bojesen, Stig E., Bolla, Manjeet K., Brauch, Hiltrud, Brenner, Hermann, Brenton, James D., Brook, Mark N., Brunet, Joan, Brunnström, Hans, Buchanan, Daniel D., Burwinkel, Barbara, Butzow, Ralf, Cadoni, Gabriella, Caldés, Trinidad, Caligo, Maria A., Campbell, Ian, Campbell, Peter T., Cancel-Tassin, Géraldine, Cannon-Albright, Lisa, Campa, Daniele, Caporaso, Neil, Carvalho, André L., Chan, Andrew T., Chang-Claude, Jenny, Chanock, Stephen J., Chen, Chu, Christiani, David C., Claes, Kathleen B. M., Claessens, Frank, Clements, Judith, Collée, J. Margriet, Correa, Marcia Cruz, Couch, Fergus J., Cox, Angela, Cunningham, Julie M., Cybulski, Cezary, Czene, Kamila, Daly, Mary B., deFazio, Anna, Devilee, Peter, Diez, Orland, Gago-Dominguez, Manuela, Donovan, Jenny L., Dörk, Thilo, Duell, Eric J., Dunning, Alison M., Dwek, Miriam, Eccles, Diana M., Edlund, Christopher K., Edwards, Digna R. Velez, Ellberg, Carolina, Evans, D. Gareth, Fasching, Peter A., Ferris, Robert L., Liloglou, Triantafillos, Figueiredo, Jane C., Fletcher, Olivia, Fortner, Renée T., Fostira, Florentia, Franceschi, Silvia, Friedman, Eitan, Gallinger, Steven J., Ganz, Patricia A., Garber, Judy, García-Sáenz, José A., Gayther, Simon A., Giles, Graham G., Godwin, Andrew K., Goldberg, Mark S., Goldgar, David E., Goode, Ellen L., Goodman, Marc T., Goodman, Gary, Grankvist, Kjell, Greene, Mark H., Gronberg, Henrik, Gronwald, Jacek, Guénel, Pascal, Håkansson, Niclas, Hall, Per, Hamann, Ute, Hamdy, Freddie C., Hamilton, Robert J., Hampe, Jochen, Haugen, Aage, Heitz, Florian, Herrero, Rolando, Hillemanns, Peter, Hoffmeister, Michael, Høgdall, Estrid, Hong, Yun-Chul, Hopper, John L., Houlston, Richard, Hulick, Peter J., Hunter, David J., Huntsman, David G., Idos, Gregory, Imyanitov, Evgeny N., Ingles, Sue Ann, Isaacs, Claudine, Jakubowska, Anna, James, Paul, Jenkins, Mark A., Johansson, Mattias, Johansson, Mikael, John, Esther M., Joshi, Amit D., Kaneva, Radka, Karlan, Beth Y., Kelemen, Linda E., Kühl, Tabea, Khaw, Kay-Tee, Khusnutdinova, Elza, Kibel, Adam S., Kiemeney, Lambertus A., Kim, Jeri, Kjaer, Susanne K., Knight, Julia A., Kogevinas, Manolis, Kote-Jarai, Zsofia, Koutros, Stella, Kristensen, Vessela N., Kupryjanczyk, Jolanta, Lacko, Martin, Lam, Stephan, Lambrechts, Diether, Landi, Maria Teresa, Lazarus, Philip, Le, Nhu D., Lee, Eunjung, Lejbkowicz, Flavio, Lenz, Heinz-Josef, Leslie, Goska, Lessel, Davor, Lester, Jenny, Levine, Douglas A., Li, Li, Li, Christopher I., Lindblom, Annika, Lindor, Noralane M., Liu, Geoffrey, Loupakis, Fotios, Lubiński, Jan, Maehle, Lovise, Maier, Christiane, Mannermaa, Arto, Marchand, Loic Le, Margolin, Sara, May, Taymaa, McGuffog, Lesley, Meindl, Alfons, Middha, Pooja, Miller, Austin, Milne, Roger L., MacInnis, Robert J., Modugno, Francesmary, Montagna, Marco, Moreno, Victor, Moysich, Kirsten B., Mucci, Lorelei, Muir, Kenneth, Mulligan, Anna Marie, Nathanson, Katherine L., Neal, David E., Ness, Andrew R., Neuhausen, Susan L., Nevanlinna, Heli, Newcomb, Polly A., Newcomb, Lisa F., Nielsen, Finn Cilius, Nikitina-Zake, Liene, Nordestgaard, Børge G., Nussbaum, Robert L., Offit, Kenneth, Olah, Edith, Olama, Ali Amin Al, Olopade, Olufunmilayo I., Olshan, Andrew F., Olsson, Håkan, Osorio, Ana, Pandha, Hardev, Park, Jong Y., Pashayan, Nora, Parsons, Michael T., Pejovic, Tanja, Penney, Kathryn L., Peters, Wilbert H. M., Phelan, Catherine M., Phipps, Amanda I., Plaseska-Karanfilska, Dijana, Pring, Miranda, Prokofyeva, Darya, Radice, Paolo, Stefansson, Kari, Ramus, Susan J., Raskin, Leon, Rennert, Gad, Rennert, Hedy S., van Rensburg, Elizabeth J., Riggan, Marjorie J., Risch, Harvey A., Risch, Angela, Roobol, Monique J., Rosenstein, Barry S., Rossing, Mary Anne, De Ruyck, Kim, Saloustros, Emmanouil, Sandler, Dale P., Sawyer, Elinor J., Schabath, Matthew B., Schleutker, Johanna, Schmidt, Marjanka K., Setiawan, V. Wendy, Shen, Hongbing, Siegel, Erin M., Sieh, Weiva, Singer, Christian F., Slattery, Martha L., Sorensen, Karina Dalsgaard, Southey, Melissa C., Spurdle, Amanda B., Stanford, Janet L., Stevens, Victoria L., Stintzing, Sebastian, Stone, Jennifer, Sundfeldt, Karin, Sutphen, Rebecca, Swerdlow, Anthony J., Tajara, Eloiza H., Tangen, Catherine M., Tardon, Adonina, Taylor, Jack A., Teare, M. Dawn, Teixeira, Manuel R., Terry, Mary Beth, Terry, Kathryn L., Thibodeau, Stephen N., Thomassen, Mads, Bjørge, Line, Tischkowitz, Marc, Toland, Amanda E., Torres, Diana, Townsend, Paul A., Travis, Ruth C., Tung, Nadine, Tworoger, Shelley S., Ulrich, Cornelia M., Usmani, Nawaid, Vachon, Celine M., Van Nieuwenhuysen, Els, Vega, Ana, Aguado-Barrera, Miguel Elías, Wang, Qin, Webb, Penelope M., Weinberg, Clarice R., Weinstein, Stephanie, Weissler, Mark C., Weitzel, Jeffrey N., West, Catharine M. L., White, Emily, Whittemore, Alice S., Wichmann, H-Erich, Wiklund, Fredrik, Winqvist, Robert, Wolk, Alicja, Woll, Penella, Woods, Michael, Wu, Anna H., Wu, Xifeng, Yannoukakos, Drakoulis, Zheng, Wei, Zienolddiny, Shanbeh, Ziogas, Argyrios, Zorn, Kristin K., Lane, Jacqueline M., Saxena, Richa, Thomas, Duncan, Hung, Rayjean J., Diergaarde, Brenda, McKay, James, Peters, Ulrike, Hsu, Li, García-Closas, Montserrat, Eeles, Rosalind A., Chenevix-Trench, Georgia, Brennan, Paul J., Haiman, Christopher A., Simard, Jacques, Easton, Douglas F., Gruber, Stephen B., Pharoah, Paul D. P., Price, Alkes L., Pasaniuc, Bogdan, Amos, Christopher I., Kraft, Peter, and Lindström, Sara
- Published
- 2019
- Full Text
- View/download PDF
136. Shared heritability and functional enrichment across six solid cancers
- Author
-
Jiang, Xia, Finucane, Hilary K., Schumacher, Fredrick R., Schmit, Stephanie L., Tyrer, Jonathan P., Han, Younghun, Michailidou, Kyriaki, Lesseur, Corina, Kuchenbaecker, Karoline B., Dennis, Joe, Conti, David V., Casey, Graham, Gaudet, Mia M., Huyghe, Jeroen R., Albanes, Demetrius, Aldrich, Melinda C., Andrew, Angeline S., Andrulis, Irene L., Anton-Culver, Hoda, Antoniou, Antonis C., Antonenkova, Natalia N., Arnold, Susanne M., Aronson, Kristan J., Arun, Banu K., Bandera, Elisa V., Barkardottir, Rosa B., Barnes, Daniel R., Batra, Jyotsna, Beckmann, Matthias W., Benitez, Javier, Benlloch, Sara, Berchuck, Andrew, Berndt, Sonja I., Bickeböller, Heike, Bien, Stephanie A., Blomqvist, Carl, Boccia, Stefania, Bogdanova, Natalia V., Bojesen, Stig E., Bolla, Manjeet K., Brauch, Hiltrud, Brenner, Hermann, Brenton, James D., Brook, Mark N., Brunet, Joan, Brunnström, Hans, Buchanan, Daniel D., Burwinkel, Barbara, Butzow, Ralf, Cadoni, Gabriella, Caldés, Trinidad, Caligo, Maria A., Campbell, Ian, Campbell, Peter T., Cancel-Tassin, Géraldine, Cannon-Albright, Lisa, Campa, Daniele, Caporaso, Neil, Carvalho, André L., Chan, Andrew T., Chang-Claude, Jenny, Chanock, Stephen J., Chen, Chu, Christiani, David C., Claes, Kathleen B. M., Claessens, Frank, Clements, Judith, Collée, J. Margriet, Correa, Marcia Cruz, Couch, Fergus J., Cox, Angela, Cunningham, Julie M., Cybulski, Cezary, Czene, Kamila, Daly, Mary B., deFazio, Anna, Devilee, Peter, Diez, Orland, Gago-Dominguez, Manuela, Donovan, Jenny L., Dörk, Thilo, Duell, Eric J., Dunning, Alison M., Dwek, Miriam, Eccles, Diana M., Edlund, Christopher K., Edwards, Digna R Velez, Ellberg, Carolina, Evans, D. Gareth, Fasching, Peter A., Ferris, Robert L., Liloglou, Triantafillos, Figueiredo, Jane C., Fletcher, Olivia, Fortner, Renée T., Fostira, Florentia, Franceschi, Silvia, Friedman, Eitan, Gallinger, Steven J., Ganz, Patricia A., Garber, Judy, García-Sáenz, José A., Gayther, Simon A., Giles, Graham G., Godwin, Andrew K., Goldberg, Mark S., Goldgar, David E., Goode, Ellen L., Goodman, Marc T., Goodman, Gary, Grankvist, Kjell, Greene, Mark H., Gronberg, Henrik, Gronwald, Jacek, Guénel, Pascal, Håkansson, Niclas, Hall, Per, Hamann, Ute, Hamdy, Freddie C., Hamilton, Robert J., Hampe, Jochen, Haugen, Aage, Heitz, Florian, Herrero, Rolando, Hillemanns, Peter, Hoffmeister, Michael, Høgdall, Estrid, Hong, Yun-Chul, Hopper, John L., Houlston, Richard, Hulick, Peter J., Hunter, David J., Huntsman, David G., Idos, Gregory, Imyanitov, Evgeny N., Ingles, Sue Ann, Isaacs, Claudine, Jakubowska, Anna, James, Paul, Jenkins, Mark A., Johansson, Mattias, Johansson, Mikael, John, Esther M., Joshi, Amit D., Kaneva, Radka, Karlan, Beth Y., Kelemen, Linda E., Kühl, Tabea, Khaw, Kay-Tee, Khusnutdinova, Elza, Kibel, Adam S., Kiemeney, Lambertus A., Kim, Jeri, Kjaer, Susanne K., Knight, Julia A., Kogevinas, Manolis, Kote-Jarai, Zsofia, Koutros, Stella, Kristensen, Vessela N., Kupryjanczyk, Jolanta, Lacko, Martin, Lam, Stephan, Lambrechts, Diether, Landi, Maria Teresa, Lazarus, Philip, Le, Nhu D., Lee, Eunjung, Lejbkowicz, Flavio, Lenz, Heinz-Josef, Leslie, Goska, Lessel, Davor, Lester, Jenny, Levine, Douglas A., Li, Li, Li, Christopher I., Lindblom, Annika, Lindor, Noralane M., Liu, Geoffrey, Loupakis, Fotios, Lubiński, Jan, Maehle, Lovise, Maier, Christiane, Mannermaa, Arto, Marchand, Loic Le, Margolin, Sara, May, Taymaa, McGuffog, Lesley, Meindl, Alfons, Middha, Pooja, Miller, Austin, Milne, Roger L., MacInnis, Robert J., Modugno, Francesmary, Montagna, Marco, Moreno, Victor, Moysich, Kirsten B., Mucci, Lorelei, Muir, Kenneth, Mulligan, Anna Marie, Nathanson, Katherine L., Neal, David E., Ness, Andrew R., Neuhausen, Susan L., Nevanlinna, Heli, Newcomb, Polly A., Newcomb, Lisa F., Nielsen, Finn Cilius, Nikitina-Zake, Liene, Nordestgaard, Børge G., Nussbaum, Robert L., Offit, Kenneth, Olah, Edith, Olama, Ali Amin Al, Olopade, Olufunmilayo I., Olshan, Andrew F., Olsson, Håkan, Osorio, Ana, Pandha, Hardev, Park, Jong Y., Pashayan, Nora, Parsons, Michael T., Pejovic, Tanja, Penney, Kathryn L., Peters, Wilbert H M., Phelan, Catherine M., Phipps, Amanda I., Plaseska-Karanfilska, Dijana, Pring, Miranda, Prokofyeva, Darya, Radice, Paolo, Stefansson, Kari, Ramus, Susan J., Raskin, Leon, Rennert, Gad, Rennert, Hedy S., van Rensburg, Elizabeth J., Riggan, Marjorie J., Risch, Harvey A., Risch, Angela, Roobol, Monique J., Rosenstein, Barry S., Rossing, Mary Anne, De Ruyck, Kim, Saloustros, Emmanouil, Sandler, Dale P., Sawyer, Elinor J., Schabath, Matthew B., Schleutker, Johanna, Schmidt, Marjanka K., Setiawan, V. Wendy, Shen, Hongbing, Siegel, Erin M., Sieh, Weiva, Singer, Christian F., Slattery, Martha L., Sorensen, Karina Dalsgaard, Southey, Melissa C., Spurdle, Amanda B., Stanford, Janet L., Stevens, Victoria L., Stintzing, Sebastian, Stone, Jennifer, Sundfeldt, Karin, Sutphen, Rebecca, Swerdlow, Anthony J., Tajara, Eloiza H., Tangen, Catherine M., Tardon, Adonina, Taylor, Jack A., Teare, M. Dawn, Teixeira, Manuel R., Terry, Mary Beth, Terry, Kathryn L., Thibodeau, Stephen N., Thomassen, Mads, Bjørge, Line, Tischkowitz, Marc, Toland, Amanda E., Torres, Diana, Townsend, Paul A., Travis, Ruth C., Tung, Nadine, Tworoger, Shelley S., Ulrich, Cornelia M., Usmani, Nawaid, Vachon, Celine M., Van Nieuwenhuysen, Els, Vega, Ana, Aguado-Barrera, Miguel Elías, Wang, Qin, Webb, Penelope M., Weinberg, Clarice R., Weinstein, Stephanie, Weissler, Mark C., Weitzel, Jeffrey N., West, Catharine M. L., White, Emily, Whittemore, Alice S., Wichmann, H-Erich, Wiklund, Fredrik, Winqvist, Robert, Wolk, Alicja, Woll, Penella, Woods, Michael, Wu, Anna H., Wu, Xifeng, Yannoukakos, Drakoulis, Zheng, Wei, Zienolddiny, Shanbeh, Ziogas, Argyrios, Zorn, Kristin K., Lane, Jacqueline M., Saxena, Richa, Thomas, Duncan, Hung, Rayjean J., Diergaarde, Brenda, McKay, James, Peters, Ulrike, Hsu, Li, García-Closas, Montserrat, Eeles, Rosalind A., Chenevix-Trench, Georgia, Brennan, Paul J., Haiman, Christopher A., Simard, Jacques, Easton, Douglas F., Gruber, Stephen B., Pharoah, Paul D. P., Price, Alkes L., Pasaniuc, Bogdan, Amos, Christopher I., Kraft, Peter, and Lindström, Sara
- Published
- 2019
- Full Text
- View/download PDF
137. Prostate cancer risk assessment by the primary care physician and urologist: transabdominal- versus transrectal ultrasound prostate volume-based use of the Rotterdam Prostate Cancer Risk Calculator
- Author
-
de Vos, Ivo I., primary, Drost, Frank-Jan H., additional, Bokhorst, Leonard P., additional, Alberts, Arnout R., additional, van Gelder, Martine, additional, Herman, Erik M., additional, Boswinkel, Wouter D., additional, Bangma, Chris H., additional, and Roobol, Monique J., additional
- Published
- 2023
- Full Text
- View/download PDF
138. The combined role of MRI prostate and prostate health index in improving detection of significant prostate cancer in a screening population of Chinese men
- Author
-
Chiu, Peter KF, primary, Lam, Thomas YT, additional, Ng, Chi-Fai, additional, Teoh, Jeremy YC, additional, Cho, Carmen CM, additional, Hung, Hiu-Yee, additional, Hong, Cindy, additional, Roobol, Monique J, additional, Chu, Winnie CW, additional, Wong, Samuel YS, additional, and Sung, Joseph JY, additional
- Published
- 2023
- Full Text
- View/download PDF
139. Germline variation at 8q24 and prostate cancer risk in men of European ancestry
- Author
-
Matejcic, Marco, Saunders, Edward J., Dadaev, Tokhir, Brook, Mark N., Wang, Kan, Sheng, Xin, Olama, Ali Amin Al, Schumacher, Fredrick R., Ingles, Sue A., Govindasami, Koveela, Benlloch, Sara, Berndt, Sonja I., Albanes, Demetrius, Koutros, Stella, Muir, Kenneth, Stevens, Victoria L., Gapstur, Susan M., Tangen, Catherine M., Batra, Jyotsna, Clements, Judith, Gronberg, Henrik, Pashayan, Nora, Schleutker, Johanna, Wolk, Alicja, West, Catharine, Mucci, Lorelei, Kraft, Peter, Cancel-Tassin, Géraldine, Sorensen, Karina D., Maehle, Lovise, Grindedal, Eli M., Strom, Sara S., Neal, David E., Hamdy, Freddie C., Donovan, Jenny L., Travis, Ruth C., Hamilton, Robert J., Rosenstein, Barry, Lu, Yong-Jie, Giles, Graham G., Kibel, Adam S., Vega, Ana, Bensen, Jeanette T., Kogevinas, Manolis, Penney, Kathryn L., Park, Jong Y., Stanford, Janet L., Cybulski, Cezary, Nordestgaard, Børge G., Brenner, Hermann, Maier, Christiane, Kim, Jeri, Teixeira, Manuel R., Neuhausen, Susan L., De Ruyck, Kim, Razack, Azad, Newcomb, Lisa F., Lessel, Davor, Kaneva, Radka, Usmani, Nawaid, Claessens, Frank, Townsend, Paul A., Gago-Dominguez, Manuela, Roobol, Monique J., Menegaux, Florence, Khaw, Kay-Tee, Cannon-Albright, Lisa A., Pandha, Hardev, Thibodeau, Stephen N., Schaid, Daniel J., The PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, Wiklund, Fredrik, Chanock, Stephen J., Easton, Douglas F., Eeles, Rosalind A., Kote-Jarai, Zsofia, Conti, David V., and Haiman, Christopher A.
- Published
- 2018
- Full Text
- View/download PDF
140. Comparison of Two Prostate Cancer Risk Calculators that Include the Prostate Health Index
- Author
-
Roobol, Monique J., Vedder, Moniek M., Nieboer, Daan, Houlgatte, Alain, Vincendeau, Sébastien, Lazzeri, Massimo, Guazzoni, Giorgio, Stephan, Carsten, Semjonow, Axel, Haese, Alexander, Graefen, Markus, and Steyerberg, Ewout W.
- Published
- 2015
- Full Text
- View/download PDF
141. Impact of Early Diagnosis of Prostate Cancer on Survival Outcomes
- Author
-
van den Bergh, Roderick C.N., Loeb, Stacy, and Roobol, Monique J.
- Published
- 2015
- Full Text
- View/download PDF
142. Nonlinear modeling was applied thoughtfully for risk prediction: the Prostate Biopsy Collaborative Group
- Author
-
Nieboer, Daan, Vergouwe, Yvonne, Roobol, Monique J., Ankerst, Donna P., Kattan, Michael W., Vickers, Andrew J., and Steyerberg, Ewout W.
- Published
- 2015
- Full Text
- View/download PDF
143. Shifting risk‐stratified early prostate cancer detection to a primary healthcare setting
- Author
-
Hogenhout, Renée, primary, Osses, Daniël F., additional, Alberts, Arnout R., additional, Buizer‐Rijksen, Hanne G., additional, Remmers, Sebastiaan, additional, and Roobol, Monique J., additional
- Published
- 2022
- Full Text
- View/download PDF
144. Sexual and urinary function in prostate cancer clinical studies and the Europa Uomo Patient Reported Outcome Study: does it match?
- Author
-
REMMERS, Sebastiaan, primary, VENDERBOS, Lionne D., additional, DESCHAMPS, André, additional, DOWLING, John, additional, CARL, Ernst-Günter, additional, and ROOBOL, Monique J., additional
- Published
- 2022
- Full Text
- View/download PDF
145. De klinische relevantie van cribriforme en intraductale prostaatkanker in diagnostische naaldbiopten
- Author
-
Kweldam, Charlotte F., Kümmerlin, Intan P., Nieboer, Daan, Verhoef, Esther I., Steyerberg, Ewout W., Incrocci, Luca, Bangma, Chris H., van der Kwast, Theodorus H., Roobol, Monique J., and van Leenders, Geert J.
- Published
- 2017
- Full Text
- View/download PDF
146. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up
- Author
-
Schröder, Fritz H, Hugosson, Jonas, Roobol, Monique J, Tammela, Teuvo L J, Zappa, Marco, Nelen, Vera, Kwiatkowski, Maciej, Lujan, Marcos, Määttänen, Liisa, Lilja, Hans, Denis, Louis J, Recker, Franz, Paez, Alvaro, Bangma, Chris H, Carlsson, Sigrid, Puliti, Donella, Villers, Arnauld, Rebillard, Xavier, Hakama, Matti, Stenman, Ulf-Hakan, Kujala, Paula, Taari, Kimmo, Aus, Gunnar, Huber, Andreas, van der Kwast, Theo H, van Schaik, Ron H N, de Koning, Harry J, Moss, Sue M, and Auvinen, Anssi
- Published
- 2014
- Full Text
- View/download PDF
147. Active Surveillance: The European Experience
- Author
-
Bul, Meelan, Roobol, Monique J., Bangma, Chris H., and Klotz, Laurence, editor
- Published
- 2012
- Full Text
- View/download PDF
148. Individual and Mass Screening
- Author
-
Bangma, Chris H., van Leeuwen, Pim J., Roobol, Monique J., Bolla, Michel, editor, and van Poppel, Hendrik, editor
- Published
- 2012
- Full Text
- View/download PDF
149. External validation of the Rotterdam prostate cancer risk calculator within a high-risk Dutch clinical cohort
- Author
-
Hagens, Marinus J., primary, Stelwagen, Piter J., additional, Veerman, Hans, additional, Rynja, Sybren P., additional, Smeenge, Martijn, additional, van der Noort, Vincent, additional, Roeleveld, Ton A., additional, van Kesteren, Jolien, additional, Remmers, Sebastiaan, additional, Roobol, Monique J., additional, van Leeuwen, Pim J., additional, and van der Poel, Henk G., additional
- Published
- 2022
- Full Text
- View/download PDF
150. Predictive Value of Cribriform and Intraductal Carcinoma for the Nomogram-based Selection of Prostate Cancer Patients for Pelvic Lymph Node Dissection
- Author
-
de Barros, Hilda A., primary, Remmers, Sebastiaan, additional, Luiting, Henk B., additional, van Leenders, Geert J.L.H., additional, Roobol, Monique J., additional, Bekers, Elise M., additional, Amin, Amer, additional, Haynes, Anne-Maree, additional, Delprado, Warick, additional, Stricker, Phillip D., additional, van der Poel, Henk G., additional, van der Kwast, Theodorus H., additional, and van Leeuwen, Pim J., additional
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.